Shares of Dare Bioscience Inc (NASDAQ:DARE) saw an uptick in trading volume on Thursday . 10,180,637 shares changed hands during mid-day trading, an increase of 1,684% from the previous session’s volume of 570,660 shares.The stock last traded at $0.98 and had previously closed at $0.85.

Several brokerages have recently issued reports on DARE. Maxim Group set a $3.00 target price on shares of Dare Bioscience and gave the company a “buy” rating in a research note on Thursday. ValuEngine raised shares of Dare Bioscience from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd.

The company has a market capitalization of $9.72 million, a price-to-earnings ratio of -0.79 and a beta of 2.37.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. As a group, sell-side analysts forecast that Dare Bioscience Inc will post -1.05 EPS for the current year.

A hedge fund recently raised its stake in Dare Bioscience stock. Citadel Advisors LLC increased its position in shares of Dare Bioscience Inc (NASDAQ:DARE) by 205.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,338 shares of the biotechnology company’s stock after acquiring an additional 71,470 shares during the quarter. Citadel Advisors LLC owned about 0.93% of Dare Bioscience worth $104,000 as of its most recent SEC filing. 7.56% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Dare Bioscience (DARE) Sees Unusually-High Trading Volume” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at

About Dare Bioscience (NASDAQ:DARE)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Recommended Story: What is the float in trading stocks?

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with's FREE daily email newsletter.